Dissecting Clot Retraction and Platelet Aggregation

CLOT RETRACTION DOES NOT REQUIRE AN INTACT FIBRINOGEN γ CHAIN C TERMINUS*

(Received for publication, December 13, 1995, and in revised form, February 16, 1996)

Michael M. Rooney, Leslie V. Parise, and Susan T. Lord

From the Departments of ‡Chemistry, §Pathology, and ¶Pharmacology, University of North Carolina, Chapel Hill, North Carolina 27599-7525

Fibrinogen mediates the processes of platelet aggregation and clot retraction. Previous studies have demonstrated that fibrinogen binding to the platelet receptor αIIbβ3 requires the C-terminal residues of the fibrinogen γ chain. We made a recombinant human fibrinogen that lacks the γ chain C-terminal four residues (AGDV). As expected this fibrinogen did not support platelet aggregation. Unexpectedly, this variant did support clot retraction that was indistinguishable from retraction with normal recombinant or plasma fibrinogen. These results suggest that the site on fibrinogen that is required for platelet aggregation differs from the site on fibrin that is required for clot retraction.

The processes of platelet aggregation and clot retraction are mediated by fibrinogen in vitro and play a role in maintaining hemostasis in vivo. Fibrinogen is a large (340 kDa) plasma protein consisting of two sets of Aα, Bβ, and γ chains. The protein is arranged in a symmetrical fashion with two lateral D domains and a central E domain (1). Previous work employing electron microscopy (2), synthetic peptides (3), and recombinant proteins (4, 5) has implicated the D domain, in particular residues γ408–411 (AGDV), as the site on fibrinogen that interacts with platelets. This interaction involves the platelet integrin αIIbβ3, a heterodimeric transmembrane receptor. Antibodies and peptides that prevent fibrinogen binding to αIIbβ3 also prevent platelet aggregation and clot retraction (6–8). Together, these findings predict that the αIIbβ3 recognition site on fibrinogen (i.e. residues γ408–411) must be present and accessible for aggregation or clot retraction to occur. Two studies support this prediction with respect to platelet aggregation (4, 5), but both have limitations. In one (4), recombinant γ chains lacking residues 408–411 were unable to support platelet aggregation; however, this variant γ chain was studied outside the context of the entire molecule. In the other (5), recombinant fibrinogen with a 20-amino acid insert in place of these four residues was unable to support platelet aggregation. However, the lack of aggregation cannot be directly attributed to the loss of the AGDV residues, as the additional 20 amino acids may sterically impair aggregation. Moreover, neither study explored the effects that these alterations may have had on clot retraction.

We report that an intact recombinant fibrinogen lacking only residues γ408–411 does not support aggregation, consistent with previous work (4, 5), but unexpectedly supports clot retraction to the same extent as normal recombinant and plasma fibrinogen. These findings suggest that other domains in fibrinogen participate in clot retraction.

MATERIALS AND METHODS

Construction of Expression Vectors—pMLP-Aα, pMLP-Bβ, and pMLP-γ encoding the Aα, Bβ, and γ chains of human fibrinogen have been described previously (9, 10). The vector pMLP-γ407 was constructed from pMLP-γ and p647, described in Hettesch et al. (11). The C-terminal nucleotides from the Escherichia coli expression vector p647(γ407), which includes a stop codon at position 408, were removed as a HindIII to BstXI fragment. The corresponding sites on pMLP-γ were cleaved with NotI and BstXI. The NotI and HindIII sites were blunt ended with T4 polymerase. The fragment from p647 was ligated into the cleaved vector to give pMLP-γ407. The resulting mammalian expression vector was sequenced using an Applied Biosystems automated sequencer (Foster City, CA). Restriction digests and general cloning procedures have been described (9).

Cell Culture—CHO transfections and growth conditions have been described (9). Normal recombinant fibrinogen, the predominant form found in human plasma, was secreted from CHO cells containing the pMLP-α, pMLP-Bβ, and pMLP-γ vectors. Cell line CHO-γ407 was constructed by transfecting pMLP-γ407 into CHO cells harboring pMLP-Aα and pMLP-Bβ. Transfected cells were selected in medium containing G418 (Life Technologies, Inc.), a neomycin analog, and histidinol (Aldrich). Fibrinogen production was monitored by enzyme-linked immunosorbent assay as described previously (9). Serum-free medium was pooled and stored at −20 °C until the fibrinogen was purified.

Purification of Recombinant Fibrinogen—Recombinant fibrinogen was purified from CHO serum-free medium as described (10). Briefly, fibrinogen was precipitated from the medium with 40% (NH4)2SO4, and the precipitate was resuspended and purified by protamine-Sepharose chromatography. Purification was monitored by electrophoresis on 8% polyacrylamide gels by the method of Laemmli (11). Western blot analysis was performed as described (9) with a polyclonal antibody that reacts with fibrinogen and its degradation products (DAKO Corporation, Carpinteria, CA) and 4A5, a monoclonal antibody specific for the C terminus of the γ chain (12). Monoclonal antibody 4A5 was the generous gift of Dr. Gary Matsueda, Bristol-Myers Squibb Pharmaceuticals (Princeton, NJ). Plasma fibrinogen was purchased from Calbiochem (La Jolla, CA).

Isolation of Human Platelets—Human blood (60 ml) from healthy volunteers who had abstained from aspirin for 10 days was collected into polypropylene tubes containing 1:7 acid/citrate/dextrose anticoagulant. Platelet-rich plasma was obtained by centrifugation at 200 × g for 25 min at ambient temperature. Prostaglandin E1 (Sigma) was added to a final concentration of 20 nM. The platelet-rich plasma was then centrifuged at 800 × g for 25 min, and the platelet pellet was resuspended in Tyrode’s buffer, pH 7.2 (10 mM Hepes, 135 mM NaCl, 2.7 mM KCl, 12 mM NaHCO3, 5.5 mM glucose, 2% bovine serum albumin (fraction V; Miles Pentex)). The platelets were applied to a Sepharose CL-2B column (Sigma) equilibrated with Tyrode’s buffer and eluted with the same buffer. The platelets were counted using a Coulter counter (Hialeah, FL) and adjusted to a final concentration of 2 × 107 ml−1 in Tyrode’s buffer with 1 mM Ca2+ and 2 mM Mg2+.

Platelet Aggregation Assay—Platelet aggregation in Tyrode’s buffer was monitored with a platelet aggregometer (Chrono-Log). Fibrinogen (final concentration, 250 nM) was added to 0.4-ml platelet suspensions (2 × 107 platelets/ml) stirred at 37 °C. Aggregation was monitored by...
(9). Gel-filtered platelets (2 × 10^8 platelets/ml) were preincubated with 300 nM fibrinogen to give a final volume of 0.5 ml. Human α-thrombin, a generous gift of Dr. Frank Church, University of North Carolina (Chapel Hill, NC), was added to a final concentration of 0.5 unit/ml. The clots formed without stirring in <5 min and were incubated at 37 °C for 15 min. The tubes were transferred to ice and photographed 1 h later. An alternative method of measuring retraction involved a modified version of the Chen et al. procedure (8). Clot length and width were measured with a ruler every 2 min following the addition of thrombin and were used to calculate clot area. Control experiments were performed in the absence of platelets or the absence of added fibrinogen. Addition of thrombin to platelet suspensions without added fibrinogen did not result in clot formation, and addition of thrombin to fibrinogen solutions in the absence of platelets resulted in a fibrin clot that did not retract.

**RESULTS AND DISCUSSION**

We characterized the purified recombinant proteins by SDS-polyacrylamide gel electrophoresis and Western blots. SDS-polyacrylamide gel electrophoresis run under reducing conditions (Fig. 1) demonstrated that all three chains were present in both the normal recombinant fibrinogen and the γ407 variant. Electrophoresis under non-reducing conditions showed that the chains assembled into a protein with a molecular mass of 340 kDa (data not shown). Western blot analysis with a polyclonal antibody (Fig. 2A) confirmed the presence of all three chains in both recombinant proteins. A duplicate blot developed with monoclonal antibody 4A5 (Fig. 2B), a monoclonal antibody specific for the C terminus of the γ chain, showed immunoreactivity with both plasma and normal recombinant fibrinogen but not with the γ407 variant. Thus, the C-terminal epitope for 4A5 has been perturbed in the γ407 variant. This result is consistent with the lack of γ chain residues 408–411, as predicted from the DNA sequence data of the γ chain expression plasmid.

We tested the recombinant proteins in platelet aggregation assays (Fig. 3). Platelets were activated upon addition of 10 μM ADP, as indicated by the initial decrease in light transmission due to platelet shape change (13). Following activation, platelet samples in the presence of normal recombinant fibrinogen exhibited a dramatic increase in light transmission due to the formation of aggregates (14). In contrast, platelets in the presence of γ407 changed shape but did not aggregate. Similar results were obtained with the addition of ADP to platelets in the absence of added fibrinogen (data not shown).

We examined clot retraction to see if the region on fibrinogen required for aggregation was also required for this seemingly related process. The clot formed in the presence of γ407 was indistinguishable from the clots formed with plasma or normal recombinant fibrinogen. Clot retraction was followed for 20 min at 37 °C. Retraction rates were similar for both normal recombinant and γ407 fibrinogen (Fig. 4). The final contracted clots formed with normal recombinant, γ407, or plasma fibrinogen.
Clot Retraction Does Not Require γ Chain AGDV

(Fig. 5) were also indistinguishable. When thrombin was added to platelet suspensions without added fibrinogen, there was no clot formation (Fig. 5). When thrombin was added to solutions of recombinant or plasma fibrinogen, fibrin clots formed but did not retract (data not shown). Thus, the residues AGDV on the γ chain of fibrinogen are apparently not required for clot retraction.

Because activation of platelets by thrombin results in the release of fibrinogen from the α-granules (15), it is possible that the platelet fibrinogen may contribute to the retraction of the clots. Therefore, we plan to perform clot retraction experiments using platelets from an a-fibrinogenemic patient, which will serve as a definitive control.

In the experiments discussed here, we used genetic engineering to produce a variant fibrinogen molecule to probe two seemingly related events. Consistent with previous results, removal of the C-terminal AGDV residues from the γ chain of fibrinogen abolished the ability of the protein to support platelet aggregation. Unexpectedly, deletion of these residues did not impair clot retraction. This finding apparently contradicts previous findings that implicate AGDV in binding to α5β3 during clot retraction. We hypothesize that α5β3 interacts with residues AGDV during aggregation and interacts with one or both of the consensus binding sequences for integrins (RGD) in the α chain during clot retraction. It has been shown that the peptide RGDS can retard clot retraction (16). Using monoclonal antibodies, other investigators have shown that inaccessible sites on fibrinogen become accessible upon conversion to fibrin (17). Perhaps the RGD sites are not accessible in fibrinogen but are exposed in the fibrin molecule. These regions on the α chain may then interact with α5β3 and mediate fibrin-platelet interactions, including clot retraction. Thus, the ligand site on fibrinogen that mediates aggregation may differ from the site on fibrin that mediates clot retraction. Yet, the platelet receptor for both processes is α5β3 (7, 8, 18). We plan to test the hypothesized role of RGD in clot retraction by analysis of additional variant fibrinogens.

In summary, we find that the γ chain C-terminal residues AGDV are critical for platelet aggregation but not for clot retraction. These findings suggest a separate role for the consensus binding sequence RGD at either position 95–97 or 572–574 on the α chain of fibrinogen. Finally, the γ407 variant may also provide a means of differentiating between platelet signaling events involved in aggregation versus clot retraction.

Acknowledgments—We thank Li Fang Ping for tissue culture work, Aldo Tabares and Jennifer Ross for preparation of plasmid pMLPγ407, and David Shock, Patricia Keely, and Christel Boudignon-Proudhon for assistance with the platelet experiments.

REFERENCES

1. Weisel, J. W., Stauffacher, C. V., Bullitt, E. & Cohen, C. (1985) Science 230, 1388–1391
2. Weisel, J. W., Nagaswami, C., Vilaire, G. & Bennett, J. S. (1992) J. Biol. Chem. 267, 16637–16643
3. Kloczewiak, M., Timmons, S. T., Lukas, T. J. & Hawiger, J. (1984) Biochemistry 23, 1767–1774
4. Hettasch, J. M., Bolyard, M. G. & Lord, S. T. (1992) Thromb. Haemostasis 68, 701–706
5. Farrell, D. H., Thiagarajan, P., Chung, D. W. & Davie, E. W. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10729–10732
6. Gartner, T. K. & Ogilvie, M. L. (1988) Thromb. Res. 49, 43–53
7. Tsuzynski, G. P., Kornec, E., Cierciweski, C., Knight, L. C., Kosh, A., Srivastava, S., Niewiarowski, S. & Walsh, P. N. (1984) J. Biol. Chem. 259, 5247–5254
8. Chen, Y., O’Toole, T. E., Leong, L., Liu, B., Diaz-Gonzalez, F. & Ginsberg, M. H. (1995) Blood 86, 2606–2615
9. Binnie, C. G., Hettasch, J. M., Strickland, E. S. & Lord, S. T. (1993) Biochemistry 32, 107–113
10. Lord, S. T., Strickland, E. S. & Jayjock, E. (1996) Biochemistry 35, 2342–2348
11. Laemmli, U. K. (1970) Nature 227, 680–685
12. Shiha, E., Lindon, N., Kushner, L., Matsueda, G. R., Hawiger, J., Kloczewiak, M., Kudryk, B. & Walsh, E. W. (1991) Am. J. Physiol. 260, C965–C974
13. O’Brien, J. R. (1966) J. Clin. Pathol. (Lond.) 19, 148–153
14. Born, G. V. R. (1962) Nature 194, 927–929
15. Heilmann, E., Houdrie, P., Pruvost, A., Paponel, A. & Norden, A. T. (1991) Arterioscler. Thromb. 11, 704–718
16. Hantgan, R. R. (1988) Biochim. Biophys. Acta 968, 36–44
17. Schielen, W. J. G., Voskuilen, M., Tessre, G. I. & Nieuwenhuizen, W. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 8951–8954
18. Phillips, D. R., Fitzgerald, L. A., Charn, I. F. & Parise, L. V. (1987) Ann. N. Y. Acad. Sci. 509, 177–187

Fig. 5. Photographs of the final retracted clots. Platelets (2 × 10⁵ platelets/ml) were preincubated with 300 nM fibrinogen (to give a final volume of 0.5 ml) at 37°C for 10 min prior to the addition of 0.5 unit/ml human α-thrombin. The clots were incubated at 37°C for 15 min and transferred to ice. The photograph was taken after 1 h. Tubes: 1, normal recombinant fibrinogen; 2, recombinant γ407 fibrinogen; 3, plasma fibrinogen; 4, no added fibrinogen.